Anazol 200/- 120 ml Suspension.

Anazol 200 mg/5 ml Suspension is a broad-spectrum prescription antimicrobial and antiprotozoal oral liquid preparation containing metronidazole as its active ingredient. Formulated specifically for patients requiring an oral liquid dosage form, it is prescribed for the treatment of susceptible anaerobic bacterial infections and protozoal parasitic conditions affecting various systems in the body.

Therapeutic Indications

Anazol Suspension acts against specific micro-organisms responsible for localized and systemic infections. Its primary clinical indications include:

• Intestinal and Extra-Intestinal Amebiasis: Treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess caused by Entamoeba histolytica.

• Giardiasis: Eradication of Giardia lamblia infections of the small intestine.

• Trichomoniasis: Treatment of symptomatic and asymptomatic infections caused by Trichomonas vaginalis.

• Anaerobic Bacterial Infections: Management of infections caused by susceptible anaerobic bacteria (such as Bacteroides species, Clostridium species, and Fusobacterium species), including abdominal, gynecological, skin, and lower respiratory tract infections.

• Dental Infections: Adjunctive therapy in acute ulcerative gingivitis and dental infections involving anaerobic organisms.

Active Ingredient 

Active Constituent

• Metronidazole (200 mg per 5 ml): Synthetic nitroimidazole antimicrobial agent.

Mechanism of Action

Metronidazole is an inactive compound (prodrug) until it enters susceptible anaerobic organisms or protozoa. Intracellularly, the nitro group of metronidazole is reduced by electron-transport proteins (such as ferredoxin).

This reduction yields short-lived, highly reactive intermediate compounds or free radicals that interact directly with bacterial and protozoal DNA. This interaction causes DNA strand breakage, loss of helical structure, and inhibition of nucleic acid synthesis, ultimately resulting in microbial cell death.

Safety & Formulation Standards

Anazol 200 mg/5 ml Suspension is formulated to meet pharmaceutical safety and quality standards:

• Liquid Formulation: Enables precise volumetric measurement and administration for pediatric patients, elderly individuals, or patients with dysphagia who have difficulty swallowing solid oral dosage forms (tablets or capsules).

• Homogenous Distribution: Formulated as a stable oral suspension to ensure accurate and uniform dosing of active metronidazole throughout the treatment course.

Usage Instructions & Dosage Guidelines

Anazol Suspension must be taken strictly in accordance with a registered medical practitioner's prescription.

Administration Guidelines

1. Shake Well: Always shake the bottle thoroughly before measuring each dose to ensure equal dispersion of the active ingredient.

2. Accurate Dosing: Use a calibrated oral syringe or measuring spoon provided with the medication to measure the exact prescribed dose in milliliters (ml). Do not use household spoons.

3. Food & Administration: May be taken with or without food. Taking it with meals or a glass of milk can minimize potential gastrointestinal upset.

4. Duration of Course: Complete the full prescribed length of therapy, even if symptoms subside early, to prevent microbial resistance or infection relapse.

Safety Precautions, Contraindications & Interactions

Contraindications

• Known hypersensitivity to metronidazole, other nitroimidazole derivatives, or any inactive excipients in the formulation.

• First trimester of pregnancy in patients treated for trichomoniasis.

Warnings & Precautions

• Alcohol Interaction (Disulfiram-like Reaction): Consumption of ethanol during metronidazole therapy and for at least 48 hours following the final dose can cause severe disulfiram-like reactions (abdominal cramps, nausea, vomiting, headaches, flushing, and tachycardia). Avoid alcohol and alcohol-containing medications.

• Neurological Monitoring: Discontinue or re-evaluate therapy if peripheral neuropathy, dizziness, vertigo, or central nervous system toxicity occurs.

• Hepatic Impairment: Patients with severe liver dysfunction metabolize metronidazole at a slower rate; dose adjustments may be required by the prescribing physician.

• Long-Term Therapy: Prolonged use requires monitoring of hematologic parameters due to the potential risk of transient leukopenia.

Product Specifications